Meeting
2019 ASCO Annual Meeting
ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.
Authors
Michael A. Thompson
Advocate Aurora Health, Milwaukee, WI
Michael A. Thompson , Susanna J. Jacobus , Shaji Kumar , Murali Janakiram , Sagar Lonial , Matthias Weiss , Natalie Scott Callander , S. Vincent Rajkumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03701321
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8052)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8052
Abstract #
TPS8052
Poster Bd #
378a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
First Author: Jonathan L. Kaufman
Poster
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
First Author: Orlando Bueno
Poster
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Sagar Lonial
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess